Molecular KRAS ctDNA Predicts Metastases and Survival in Pancreatic Cancer: A Prospective Cohort Study

被引:0
作者
Leiting, Jennifer L. [1 ]
Alva-Ruiz, Roberto [1 ]
Yonkus, Jennifer A. [1 ]
Abdelrahman, Amro M. [1 ]
Lynch, Isaac T. [1 ]
Carlson, Danielle M. [1 ]
Carr, Ryan M. [2 ]
Salomao, Diva R. [3 ]
Mcwilliams, Robert R. [2 ]
Starlinger, Patrick P. [1 ]
Thiels, Cornelius A. [1 ]
Grotz, Travis E. [1 ]
Warner, Susanne G. [1 ]
Cleary, Sean P. [4 ]
Kendrick, Michael L. [1 ]
Smoot, Rory L. [1 ]
Kipp, Benjamin R. [3 ]
Truty, Mark J. [1 ]
机构
[1] Mayo Clin, Dept Surg, Div Hepatobiliary & Pancreas Surg, Rochester, MN 55905 USA
[2] Mayo Clin, Dept Med Oncol, Rochester, MN USA
[3] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA
[4] Univ Toronto, Div Gen Surg, Toronto, ON, Canada
关键词
Pancreatic cancer; Pancreatic cancer staging; Molecular staging; Staging laparoscopy; Circulating tumor DNA; KRAS mutation; CIRCULATING TUMOR DNA; ADJUVANT CHEMOTHERAPY; NEOADJUVANT THERAPY; PERITONEAL CYTOLOGY; STAGING LAPAROSCOPY; GEMCITABINE; MUTATIONS; MARKER; YIELD;
D O I
10.1245/s10434-025-17036-y
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundPatients with pancreatic ductal adenocarcinoma (PDAC) commonly have occult metastatic dissemination and current standard staging methods have significant limitations in identifying these patients. A clinically available assay allows for the identification of mutant KRAS (mKRAS) circulating tumor DNA (ctDNA) from patient plasma and peritoneal fluid that may identify these patients and impact treatment decision making. We investigated the patterns of diagnostic and prognostic capabilities of mKRAS ctDNA in patients with localized PDAC.MethodsPatients with non-metastatic PDAC were identified and underwent a full staging work-up during their first visit at our institution. Development of metastatic disease and long-term survival outcomes were assessed to compare between the mKRAS testing groups.ResultsBetween 2018 and 2022, 785 patients were evaluated. Among the 785 patients who underwent plasma mKRAS testing, 104 were mKRAS positive. Plasma mKRAS-positive patients were more likely to develop metastatic disease and had worse overall survival. In the 419 patients who underwent peritoneal mKRAS, 123 were mKRAS-positive and were more likely to harbor occult metastases or develop peritoneal rather than hematogenous metastases. For patients who underwent both baseline plasma and peritoneal mKRAS testing, any positive mKRAS test regardless of compartment was associated with worse outcomes.ConclusionsDetection of mKRAS ctDNA in plasma and peritoneal fluid of patients with localized PDAC is not only feasible but also identifies those at high risk of metastatic progression and worse survival outcomes. It allows for better prognostication and can significantly impact subsequent treatment decisions, particularly in patients where an aggressive surgical approach is being considered.
引用
收藏
页码:4453 / 4463
页数:11
相关论文
共 50 条
[21]   Pathological Response Predicts Survival after Pancreatectomy following Neoadjuvant FOLFIRINOX for Pancreatic Cancer [J].
Jeon, Hyun Jeong ;
Jeong, Hye Jeong ;
Lim, Soo Yeun ;
Yoon, So Jeong ;
Kim, Hongbeom ;
Han, In Woong ;
Heo, Jin Seok ;
Shin, Sang Hyun .
CANCERS, 2023, 15 (01)
[22]   CHD7 Expression Predicts Survival Outcomes in Patients with Resected Pancreatic Cancer [J].
Colbert, Lauren E. ;
Petrova, Aleksandra V. ;
Fisher, Sarah B. ;
Pantazides, Brooke G. ;
Madden, Matthew Z. ;
Hardy, Claire W. ;
Warren, Matthew D. ;
Pan, Yunfeng ;
Nagaraju, Ganji P. ;
Liu, Elaine A. ;
Saka, Burcu ;
Hall, William A. ;
Shelton, Joseph W. ;
Gandhi, Khanjan ;
Pauly, Rini ;
Kowalski, Jeanne ;
Kooby, David A. ;
El-Rayes, Bassel F. ;
Staley, Charles A., III ;
Adsay, N. Volkan ;
Curran, Walter J., Jr. ;
Landry, Jerome C. ;
Maithel, Shishir K. ;
Yu, David S. .
CANCER RESEARCH, 2014, 74 (10) :2677-2687
[23]   Cohort Study of Antihyperglycemic Medication and Pancreatic Cancer Patients Survival [J].
Dulskas, Audrius ;
Patasius, Ausvydas ;
Linkeviciute-Ulinskiene, Donata ;
Zabuliene, Lina ;
Smailyte, Giedre .
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2020, 17 (17) :1-11
[24]   Absence of Pancreatic Intraepithelial Neoplasia Predicts Poor Survival After Resection of Pancreatic Cancer [J].
Hassid, Benjamin G. ;
Lucas, Aimee L. ;
Salomao, Marcela ;
Weng, Chunhua ;
Liu, Feng ;
Khanna, Lauren G. ;
Kumar, Sheila ;
Hwang, Caroline ;
Chabot, John A. ;
Frucht, Harold .
PANCREAS, 2014, 43 (07) :1073-1077
[25]   Molecular pro fi ling of ctDNA in pancreatic cancer: Opportunities and challenges for clinical application [J].
Sivapalan, L. ;
Kocher, H. M. ;
Ross-Adams, H. ;
Chelala, C. .
PANCREATOLOGY, 2021, 21 (02) :363-378
[26]   The Role of Pancreatic Enzyme Replacement Therapy in Unresectable Pancreatic Cancer A Prospective Cohort Study [J].
Saito, Tomotaka ;
Hirano, Kenji ;
Isayama, Hiroyuki ;
Nakai, Yousuke ;
Saito, Kei ;
Umefune, Gyotane ;
Akiyama, Dai ;
Watanabe, Takeo ;
Takagi, Kaoru ;
Hamada, Tsuyoshi ;
Takahara, Naminatsu ;
Uchino, Rie ;
Mizuno, Suguru ;
Kogure, Hirofumi ;
Matsubara, Saburo ;
Yamamoto, Natsuyo ;
Tada, Minoru ;
Koike, Kazuhiko .
PANCREAS, 2017, 46 (03) :341-346
[27]   Are Lymph Node Metastases Associated With Survival in Black Patients With Pancreatic Cancer? [J].
Fang, Hua Amanda ;
Irfan, Ahmer ;
Vickers, Selwyn M. ;
Gbolahan, Olumide ;
Williams, Grant R. ;
Outlaw, Darryl ;
Wang, Thomas Nien-Tsu. ;
Dudeja, Vikas ;
Rose, J. Bart ;
Reddy, Sushanth .
JOURNAL OF SURGICAL RESEARCH, 2023, 284 :143-150
[28]   Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer [J].
An, Xin ;
Ding, Pei-Rong ;
Li, Yu-Hong ;
Wang, Feng-Hua ;
Shi, Yan-Xia ;
Wang, Zhi-Qiang ;
He, You-Jian ;
Xu, Rui-Hua ;
Jiang, Wen-Qi .
BIOMARKERS, 2010, 15 (06) :516-522
[29]   Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1) [J].
Xia, Liang ;
Mei, Jiandong ;
Kang, Ran ;
Deng, Senyi ;
Chen, Yaohui ;
Yang, Ying ;
Feng, Gang ;
Deng, Yulan ;
Gan, Fanyi ;
Lin, Yidan ;
Pu, Qiang ;
Ma, Lin ;
Lin, Feng ;
Yuan, Yong ;
Hu, Yang ;
Guo, Chenglin ;
Liao, Hu ;
Liu, Chengwu ;
Zhu, Yunke ;
Wang, Wenping ;
Liu, Zheng ;
Xu, Yuyang ;
Li, Kaidi ;
Li, Chuan ;
Li, Qingyun ;
He, Ji ;
Chen, Weizhi ;
Zhang, Xiaolong ;
Kou, Yingli ;
Wang, Yun ;
Wu, Zhu ;
Che, Guowei ;
Chen, Longqi ;
Liu, Lunxu .
CLINICAL CANCER RESEARCH, 2022, 28 (15) :3308-3317
[30]   Circulating tumor DNA in unresectable pancreatic cancer is a strong predictor of first-line treatment efficacy: The KRASCIPANC prospective study [J].
Evrard, Camille ;
Ingrand, Pierre ;
Rochelle, Tristan ;
Martel, Marine ;
Tachon, Gaelle ;
Flores, Nicolas ;
Randrian, Violaine ;
Ferru, Aurelie ;
Haineaux, Paul-Arthur ;
Goujon, Jean-Michel ;
Karayan-Tapon, Lucie ;
Tougeron, David .
DIGESTIVE AND LIVER DISEASE, 2023, 55 (11) :1562-1572